Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study

Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study

Aim: To evaluate pharmacokinetics, efficacy and safety of fixed-dose combination (FDC) of oral capecitabine + cyclophosphamide in metastatic breast cancer (MBC) patients progressing after anthracycline and/or taxane chemotherapy. Methods: In this prospective, adaptive, phase-2/3, open-label study (C...

Full description

Bibliographic Details
Main Authors: Sudeep Gupta, Ghanashyam Biswas, Suresh Babu, Tanveer M. Maksud, Kuntegowdennahalli C. Lakshmaiah, Jayanti G. Patel, Gopal Raja, Rakesh R. Boya, Pramod Patil, Kakali Choudhury, Shailesh A. Bondarde, Rakesh S. Neve, Guruprasad Bhat, Gopichand Mamillapalli, Apurva A. Patel, Piyush Patel, Nisarg Joshi, Vinay Bajaj, Mujtaba A. Khan
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Breast
Subjects:
Capecitabine
Cyclophosphamide
FDC
Fixed-dose combination
MBC
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621004690

Internet

http://www.sciencedirect.com/science/article/pii/S0960977621004690

Similar Items